Introduction
============

The global prevalence of diabetes in adults has been estimated at 8.5%, with as many as 422 million adults living with diabetes in 2014.[@b1-jpr-11-1857] Diabetic peripheral neuropathy, which occurs in up to 50% of patients with diabetes,[@b2-jpr-11-1857] is a cause of increased morbidity and mortality and reduced quality of life.[@b3-jpr-11-1857] Manifestations of diabetic peripheral neuropathy include pain, numbness, paresthesia, and insensitivity,[@b2-jpr-11-1857],[@b4-jpr-11-1857] leading to an increased risk for burns and other foot injuries and an impact on quality of life in areas that include sleep, enjoyment of life, and daily activities.[@b2-jpr-11-1857] Neuropathic pain is one of the most frequent complications of diabetes,[@b5-jpr-11-1857],[@b6-jpr-11-1857] and up to 22% of Japanese diabetic patients have painful diabetic neuropathy.[@b7-jpr-11-1857] A recent study reported that the prevalence of neuropathy, nephropathy, or retinopathy waŝ30%, with 6.4% of patients having all three microvascular complications.[@b8-jpr-11-1857]

Currently, pregabalin, duloxetine and tricyclic antidepressants are the recommended first-line drugs for moderate to severe painful neuropathy by the Japanese guidelines for neuropathic pain management.[@b9-jpr-11-1857] Furthermore, duloxetine and pregabalin are listed as the first-line of treatment in the international treatment guidelines for diabetic peripheral neuropathic pain (DPNP).[@b10-jpr-11-1857],[@b11-jpr-11-1857]

Duloxetine (40--60 mg daily) is approved for the treatment of DPNP in Japan. It is a serotonin and norepinephrine reuptake inhibitor and, although the exact mechanisms of the central pain inhibitory actions of duloxetine are unknown, its mechanism of action is believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS such as descending inhibitory pain pathways.[@b12-jpr-11-1857] In Japan, duloxetine is indicated for the treatment of depression and depressive state and for pain associated with diabetic neuropathy, fibromyalgia, chronic lower back pain, and osteoarthritis. In the USA, the indications for duloxetine are major depressive disorder (MDD), general anxiety disorder (GAD), DPNP, fibromyalgia, and chronic musculoskeletal pain. In the European Union, the indications for duloxetine are MDD, GAD, DPNP, and stress urinary incontinence.

Pregabalin (300--600 mg daily) is approved for the treatment of neuropathic pain and pain associated with fibro-myalgia in Japan. It is thought to reduce pain by binding to alpha-2-delta subunits of presynaptic neuronal calcium channels and reducing the release of excitatory neurotransmitters involved in pain perception.[@b13-jpr-11-1857],[@b14-jpr-11-1857] In the USA and European Union, pregabalin is indicated for the management of neuropathic pain, including DPNP, postherpetic neuralgia, fibromyalgia, and generalized anxiety disorder, and as an adjunct therapy for epilepsy.

A previous "combination vs monotherapy of pregabalin and duloxetine in diabetic neuropathy" (COMBO-DN) study combined both duloxetine (60--120 mg/day) and pregabalin (300--600 mg/day) in the treatment of patients with DPNP who were not responding to standard doses of duloxetine or pregabalin.[@b15-jpr-11-1857] They examined if a combination of both medications was superior to increasing each drug to its maximum recommended dose. The COMBO-DN study included duloxetine and pregabalin in monotherapy phase, and its primary objective was to compare efficacy between high-dose monotherapy and combination therapy. Although the COMBO-DN study compared duloxetine and pregabalin directly as a secondary endpoint in the first period of the study, the primary objective was not a direct comparison between duloxetine and pregabalin nor were there any Japa-nese patients enrolled in the study.[@b15-jpr-11-1857] The sensitivity to pain in Japanese patients is suggested to be different from that in Western patients.[@b16-jpr-11-1857] However, there is no evidence showing a direct comparison between duloxetine and pregabalin in Japanese patients. It is useful to compare the efficacy and safety of these treatments for daily medical practice. The effectiveness of various pharmacological interventions for DPNP has been evaluated; however, the implications of the findings are limited due to indirect comparisons of clinical trials.[@b17-jpr-11-1857] Treatments for DPNP in terms of effectiveness have rarely been compared directly against each other, and network meta-analysis and direct (head-to-head) comparisons can help determine the proportional advantages of given drugs.[@b18-jpr-11-1857] There is no head-to-head study comparing duloxetine and pregabalin in the treatment of Japanese patients with DPNP.

Our objective was to assess the noninferiority of duloxetine compared to pregabalin after 12 weeks of treatment in adult patients with DPNP in Japan. Both have been evaluated as first-line treatments for patients with neuropathic pain[@b6-jpr-11-1857],[@b9-jpr-11-1857] despite different modes of action. We conducted a postmarketing, Phase IV, multicenter, randomized, double-blind, parallel-group, flexible-dose, comparative study in patients who had never taken either drug and were primarily indicated for first-line treatment of DPNP. The primary objective of the study was to assess the noninferiority of duloxetine (40--60 mg/day, approved treatment doses in Japan) compared with pregabalin (300--600 mg/day) after 12 weeks of treatment in adult patients with DPNP in Japan. The study presented here is the first of its kind to directly compare the efficacy of duloxetine with pregabalin and address whether duloxetine is not inferior to pregabalin in terms of efficacy in treating DPNP after 12 weeks of treatment in adult patients.

Materials and methods
=====================

Study design
------------

This was a postmarketing, Phase IV, multicenter, randomized, double-blind, parallel-group, flexible-dose, comparative 12-week study in adult outpatients with DPNP in Japan. The study was conducted in 78 study centers, and the trial has been registered at [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT02417935). The study was approved by applicable ethical review boards and Pharmaceuticals and Medical Devices Agency prior to the study initiation, and was conducted following applicable laws and regulations, Good Clinical Practice (according to the International Conference on Harmonization), and the Declaration of Helsinki. Patients provided written consent after the study was explained and before study procedures were initiated.

Study population
----------------

The study included male or female outpatients ≥20 and \<80 years of age who presented with pain due to distal symmetrical polyneuropathy caused by type 1 or type 2 diabetes mellitus and who had never been treated with duloxetine or pregabalin. We used the Japanese abbreviated diagnostic criteria to define diabetic polyneuropathy.[@b19-jpr-11-1857] Patients had to have a score of ≥4 on the mean 24-hour average pain score measured using the 11-point numeric rating scale (NRS) in the daily patient diary (calculated from records 7 days immediately before randomization), and HbA1c ≤9.4% (National Glycohemoglobin Standardization Program). Patients had to complete daily diary entries ≥80% of the time from screening to randomization.

Key exclusion criteria included patients who had poor glycemic control within 70 days immediately prior to visit 1 (week −2 to week −1), a history or current diagnosis of psychiatric diseases including MDD, complications of diseases that were considered to affect the assessment of DPNP, and neuropathic pain suspected to be caused by alcohol.

Treatment protocol
------------------

The study consisted of four study periods, which included a 1- to 2-week screening period, a 12-week treatment period, a 1-week tapering period, and a 1-week follow-up period ([Figure 1](#f1-jpr-11-1857){ref-type="fig"}).

After screening, eligible patients were randomized and the treatment period began at week 0 (baseline, visit 2) and ended at week 12 (visit 6). At week 0 (visit 2), patients were assigned to duloxetine or pregabalin in a 1:1 ratio via a computer-generated random sequence using an interactive web response system. Randomization was stratified by the baseline weekly mean of the 24-hour average pain score (NRS) (\<6, ≥6) and by the duration of DPNP (\<2 years, ≥2 years). Duloxetine was administered at 20 mg/day for a week followed by 40 mg/day for 3 weeks. Pregabalin was administered at 150 mg/day for a week, followed by 300 mg/day for 3 weeks. To maintain blinding, patients received both their assigned active study drug and an indistinguishable placebo ("double-dummy" design). Investigators and other study personnel were also blinded to treatment allocation. At week 4 (visit 4) and week 8 (visit 5), duloxetine and pregabalin doses could be increased in patients who did not achieve clinically significant improvement (≥30% pain improvement in the Japanese validated Brief Pain Inventory-Severity and Interference rating short form \[BPI-SF\][@b20-jpr-11-1857] average pain score compared with baseline \[week 0\] score). At either week, duloxetine could be increased to 60 mg/day and pregabalin could be increased to 450 mg/day. If pregabalin was increased to 450 mg/day at week 4, it could be further increased to 600 mg/day at week 8. Once increased, patient doses could not be decreased again during the study.

During the tapering period (to minimize discontinuation-emergent adverse events), study drug doses were tapered down, and during the follow-up period, no study drug was administered.

Outcome measures
----------------

The primary efficacy measure was the 11-point NRS in the daily patient diary, ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The mean scores of the daily NRS recorded in the diaries were calculated by week, and they were used for the analyses. The NRS measured the severity of pain over the previous 24 hours (ie, "24-hour NRS average pain score"). Change in the weekly mean of the 24-hour NRS average pain score (ie, "average pain") was the primary endpoint, and noninferiority of duloxetine compared with pregabalin was assessed with the change in average pain using the NRS from baseline to week 12.

Secondary measures derived from the pain diaries were worst pain and night pain ratings. Other secondary measures included the BPI-SF that measures the severity of pain (worst pain, least pain, average pain, and pain right now) and the interference of pain on function (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life), and were recorded at baseline and weeks 2, 4, 8, and 12. Neuropathic Pain Symptom Inventory (NPSI)[@b21-jpr-11-1857] that assessed five different dimensions of neuropathic pain (burning spontaneous pain, pressing spontaneous pain, paroxysmal pain, evoked pain, and par-esthesia/dysesthesia) was recorded at baseline and week 12. The EuroQol 5-Dimension (EQ-5D)[@b22-jpr-11-1857] index score that assessed the patient's health utility (mobility, self-care, usual activities, pain and discomfort, and depression/anxiety) was recorded and a quality of life VAS score was also measured at baseline and week 12. The Clinical Global Impression of Improvement (CGI-I)[@b23-jpr-11-1857] and Patient Global Impression of Improvement (PGI-I)[@b23-jpr-11-1857] were recorded at weeks 2, 4, 8 and 12, and reflected the change from baseline. The Beck Depression Inventory-II,[@b24-jpr-11-1857] which indicates the presence and degree of depressive symptoms, was recorded at baseline and weeks 4, 8, and 12. Response to treatment was defined by a 30% and 50% reduction in average pain measured using the NRS at endpoint. Overall, the outcome measures used in this study were similar to those used in previous Phase III clinical trials of duloxetine and pregabalin.[@b25-jpr-11-1857],[@b26-jpr-11-1857]

Safety measures included frequencies of treatment-emergent adverse drug reactions (TEADRs), serious adverse events (SAEs), and laboratory measurements. The TEADRs were determined by study investigators and SAEs were defined by the protocol.

Statistical analyses
--------------------

Sample size was calculated to have enough power to confirm the noninferiority of duloxetine to pregabalin, based on the primary endpoint. Assuming that the treatment difference was 0.1 (ie, duloxetine was superior to pregabalin by 0.1) and the common SD was 1.82 with a noninferiority margin of 0.51, 141 patients per group would have had a statistical power of 80% to confirm noninferiority with a 1-sided significance level of 0.025.

The noninferiority margin was estimated based on a meta-analysis of randomized placebo-controlled trials of pregabalin in Japan and overseas. The noninferiority margin was set using half of the estimated mean difference, 0.51.

All randomized patients receiving at least 1 dose of the study drug were included in the analysis. For each analysis, the patients with no available data of the item were excluded. Analyses based on the per-protocol set were also performed to examine the robustness of the primary efficacy analysis. For this analysis, patients who had major protocol deviations, such as noncompliance of study drug or use of prohibited concomitant medication, were excluded.

A mixed model repeated measures (MMRM) analysis was used for the assessment of the primary endpoint. The MMRM model included the random effect of patient and fixed categorical effects of treatment, duration of DPNP (\<2 years, ≥2 years), week, and treatment-by-week interaction, as well as the continuous fixed covariates of baseline value. A 95% confidence interval (CI) for the treatment difference (duloxetine--pregabalin) at week 12 was estimated, and if the upper bound of the 95% CI did not exceed the predefined noninferiority margin (0.51), it could be concluded that duloxetine was not inferior to pregabalin.

For the secondary repeated efficacy endpoints, a similar MMRM model was used, but without the baseline value in the model for CGI-I and PGI-I, with the week being replaced by visit except for items from the diary. For the change from baseline to endpoint in NPSI, EQ-5D, and laboratory measurements, analysis of covariance was used. The model included treatment, duration of DPNP and baseline value for efficacy endpoints, and treatment and baseline value for laboratory measurements.

All statistical analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Patient disposition and baseline characteristics
------------------------------------------------

In this study that was conducted from April 2015 to May 2017, a total of 303 patients were randomly assigned to duloxetine and pregabalin treatment groups ([Figure 2](#f2-jpr-11-1857){ref-type="fig"}). Of the 303 patients who received the treatment, 152 patients received at least one dose of duloxetine (40--60 mg/day) and 151 patients received at least one dose of pregabalin (300--600 mg/day). During the treatment period, 15 of 152 patients (9.9%) in the duloxetine group and 21 of 151 patients (13.9%) in the pregabalin group discontinued the study. The reasons for discontinuation were balanced between groups ([Figure 2](#f2-jpr-11-1857){ref-type="fig"}), with the most common reason being discontinuation due to adverse events.

Patient demographics and baseline characteristics were generally well balanced, with no major differences between treatment groups ([Table 1](#t1-jpr-11-1857){ref-type="table"}). Of the 303 patients, 59 (19.5%) had received a previous medication, most commonly epalrestat (9.9%). In the pregabalin group, 2.0% (3/151) of patients had previously taken an investigational drug, compared with 7.9% (12/152) of patients in the duloxetine group (*P*=0.031). No statistically significant differences between treatment groups were observed for any other previous medication or for any of the baseline pain severity measures.

Extent of exposure
------------------

The number of patients receiving each dose in each treatment group for week 4 and week 8, and the maximum individual dose received are shown in [Table 2](#t2-jpr-11-1857){ref-type="table"}. In the duloxetine group, at week 4, 83 patients (58.5%) were receiving the 40 mg/day dose and 59 patients (41.5%) had increased the dose to 60 mg/day. At week 8, the proportion of patients receiving each dose remained similar, with 76 patients (54.3%) receiving the 40 mg/day dose and 64 patients (45.7%) receiving the 60 mg/day dose.

In the pregabalin group, at week 4, 90 patients (62.5%) were receiving the 300 mg/day dose and 54 patients (37.5%) had increased the dose to 450 mg/day. At week 8, 78 patients (57.4%) were receiving the 300 mg/day dose, 37 patients (27.2%) were receiving the 450 mg/day dose and 21 patients (15.4%) were receiving the 600 mg/day dose.

Efficacy
--------

### Primary efficacy measure

In the analysis of the 24-hour NRS average pain scores using an 11-point NRS in the daily patient diary by MMRM, the least-squares mean (standard error \[SE\]) change in 24-hour NRS average pain at the end of the study period (week 12) was −2.286 (0.133) in the duloxetine group and −2.358 (0.133) in the pregabalin group ([Figure 3](#f3-jpr-11-1857){ref-type="fig"}). The treatment difference was 0.072 (95% CI: −0.295, 0.439), and the upper bound of the 95% CI (0.439) did not exceed the predefined noninferiority margin (0.51), demonstrating the noninferiority of duloxetine compared with pregabalin. In the per-protocol set, the noninferiority of duloxetine compared to pregabalin was also demonstrated to show the robustness of the primary efficacy analysis (data not shown).

### Secondary efficacy measures

The mean changes from baseline to week 12, for the secondary outcome measures, are shown in [Table 3](#t3-jpr-11-1857){ref-type="table"}. For measures, such as night pain and worst pain scores, BPI-SF, CGI-I, PGI-I, and NPSI, both the duloxetine and pregabalin treatment groups showed an improvement from baseline, with no significant between-group difference. Similarly, both treatment groups showed improvement from baseline on the health outcome measures, and no significant between-group differences were observed in the EQ-5D index and VAS scores.

Proportions of patients with ≥30% or ≥50% reduction in 24-hour NRS average pain score
-------------------------------------------------------------------------------------

When treatment groups were compared with respect to the proportions of patients achieving a ≥30% or ≥50% reduction on the 24-hour NRS average pain score, in the duloxetine group, 65.8% (100/152) of patients achieved a ≥30% reduction compared to 63.1% (94/149) of patients in the pregabalin group ([Figure 4](#f4-jpr-11-1857){ref-type="fig"}). In addition, in the duloxetine group, 40.8% (62/152) of patients achieved a ≥50% reduction compared to 41.6% (62/149) of patients in the pregabalin group.

Safety
------

### Treatment-emergent adverse drug reactions

Patients generally tolerated the treatment well, with no new safety concerns or events reported as related to duloxetine. The TEADRs reported in ≥3 patients in any treatment group are shown in [Table 4](#t4-jpr-11-1857){ref-type="table"}. More patients in the pregabalin group (54 \[35.8%\]) than in the duloxetine group (45 \[29.6%\]) reported TEADRs. In the duloxetine group, the most common TEADRs reported in three or more patients were somnolence (18 \[11.8%\]), nausea (11 \[7.2%\]), dizziness (6 \[3.9%\]), vomiting (3 \[2.0%\]), stomatitis (3 \[2.0%\]), headache (3 \[2.0%\]), and decreased appetite (3 \[2.0%\]). In the pregaba-lin group, the most common TEADRs reported in three or more patients were somnolence (22 \[14.6%\]), dizziness (16 \[10.6%\]), nausea (5 \[3.3%\]), feeling abnormal (4 \[2.6%\]), edema peripheral (3 \[2.0%\]), and vertigo (3 \[2.0%\]).

### Adverse events leading to discontinuation

The incidence of adverse events leading to discontinuation was low overall (duloxetine: 10 \[6.6%\], pregabalin: 12 \[7.9%\]), and similar between the treatment groups (*P*=0.665). The most common adverse events leading to discontinuation were nervous system disorders (duloxetine: 1 \[0.7%\], pregabalin: 5 \[3.3%\]) and gastrointestinal system disorders (duloxetine: 1 \[0.7%\], pregabalin: 3 \[2.0%\]).

### SAEs and deaths

SAEs were reported in fewer patients in the duloxetine group (1 \[0.7%\]) compared with the pregabalin group (6 \[4.0%\]). In the duloxetine group, a vascular disorder (shock, 1 \[0.7%\]) was reported as an SAE, and in the pregabalin group, most SAEs were classified as gastrointestinal disorders (3 \[2.0%\]). All SAEs were reported in one patient each and were not considered possibly related to study drug, except for congestive cardiac failure (1 \[0.7%\]) and myocardial infarction (1 \[0.7%\]) (accompanied by a clinically significant abnormal electrocardiogram) which both occurred in the same patient in the pregabalin group. Both of these events were considered possibly related to study drug, and the myocardial infarction led to discontinuation. No deaths were reported during this study.

### Abnormal laboratory values

The analyses of treatment-emergent abnormal laboratory measures demonstrated that significantly more duloxetine-treated patients experienced abnormally low uric acid compared with pregabalin-treated patients (10 \[6.7%\] vs 2 \[1.4%\], respectively; *P*=0.035). No other laboratory measures showed statistically significant differences between treatment groups.

### Changes in HbA1c and glucose from baseline

The changes in HbA1c and glucose from baseline to endpoint are shown in [Table 5](#t5-jpr-11-1857){ref-type="table"}. The change in HbA1c (duloxetine: 0.17%, pregabalin: 0.14%) was statistically significant in both treatment groups, as was the change in non-fasting glucose (duloxetine: 1.30 mmol/L, pregabalin: 0.85 mmol/L). The change in fasting glucose was statistically significant in the duloxetine group (0.81 mmol/L), but not in the pregabalin group (0.17 mmol/L). Despite these changes, glucose levels remained within the normal range.

Discussion
==========

This 12-week, postmarketing, Phase IV, multicenter, ran-domized, double-blind, parallel-group, flexible-dose study demonstrated the noninferiority of duloxetine compared with pregabalin for pain relief in patients with DPNP, as measured by the change from baseline in the 24-hour NRS average pain score.

The noninferiority of duloxetine was supported by most secondary efficacy measures including night pain and worst pain scores, response rate based on change in 24-hour NRS average pain scores, BPI-SF, CGI-I, PGI-I, and NPSI. Similarly, for health outcome measures, both duloxetine and pregabalin showed improvement from baseline for the EQ-5D index and VAS scores, but with no significant difference between groups. The safety analyses of TEADRs and clinical laboratory tests showed acceptable tolerability and safety profiles for duloxetine and pregabalin. Generally, no new or unexpected safety observations were seen with regard to duloxetine treatment. The TEADRs reported in both treatment groups were consistent with the respective drug profiles. The incidence of adverse events leading to discontinuation was generally consistent with those most frequently reported in each treatment group and respective drug profile.

The efficacy and safety of both duloxetine and pregabalin in Japanese patients with DPNP have been confirmed previously by Phase III studies.[@b25-jpr-11-1857],[@b26-jpr-11-1857] However, the study presented here is the first to demonstrate the noninferiority of duloxetine compared to pregabalin in Japanese patients with DPNP. These results support the National Institute for Health and Care Excellence[@b10-jpr-11-1857],[@b11-jpr-11-1857] and the Japan Diabetes Society[@b9-jpr-11-1857] guidelines, which recommend duloxetine and pregabalin as first-line pharmaceutical treatments for DPNP. Differences in the safety profiles of duloxetine and pregabalin give physicians more treatment options for patients with DPNP.

Our results are similar to those of a previous Phase III study in patients with DPNP in Japan, where duloxetine showed superiority over placebo in reducing pain scores and improving health outcome measures.[@b25-jpr-11-1857] In that study, duloxetine (40--60 mg/day) demonstrated significantly greater improvement in average pain scores over 12 weeks compared with placebo.[@b25-jpr-11-1857] Similarly, a previous 14-week, randomized, placebo-controlled study with pregabalin (300--600 mg/day) also demonstrated efficacy in reducing pain in Japanese patients with DPNP.[@b26-jpr-11-1857] In a 12-week, open-label study in patients with an inadequate response to gabapentin, duloxetine was noninferior to pregabalin for the treatment of pain in patients with DPNP.[@b27-jpr-11-1857] Overall, the findings from these studies support the results from our study.

The COMBO-DN study examined whether a combination of duloxetine and pregabalin would be superior to increasing each drug to its maximum dose in patients with DPNP who were not responding to standard doses.[@b15-jpr-11-1857] Patients received duloxetine 60 mg/day or pregabalin 300 mg/day for 8 weeks, followed by 8 weeks of treatment with duloxetine 120 mg/day, pregabalin 600 mg/day, or a combination of duloxetine 60 mg/day and pregabalin 300 mg/day. This study found that there were no significant differences between combination and high-dose monotherapy for the primary outcome measure Brief Pain Inventory Modified Short Form, although most secondary endpoints favored combination therapy. Although our study did not use combination therapy, future examination of combination therapy in Japanese patients would be useful.

Unlike in our study, exploratory analyses of the COMBO-DN study found that improvement in pain relief during the first 8 weeks was greater with duloxetine 60 mg/day than with pregabalin 300 mg/day.[@b15-jpr-11-1857] In addition, in a network meta-analysis, serotonin and norepinephrine reuptake inhibitors were more effective than anticonvulsants in the treatment of DPNP.[@b18-jpr-11-1857] Differences in the doses and study designs may account for the different results between studies.

As in the study reported here, a previous 12-week open-label study has also shown that duloxetine and pregabalin were generally safe and tolerable in the treatment of DPNP.[@b28-jpr-11-1857] However, discontinuation due to adverse events was significantly greater in the duloxetine group (19.6%) compared with the pregabalin group (10.4%),[@b28-jpr-11-1857] whereas in our study, discontinuation due to adverse events was lower and similar between treatment groups (duloxetine: 6.6%, pregabalin: 7.9%). In our study, HbA1c significantly increased from baseline in both treatment groups, with no difference between groups, similar to a previous study comparing duloxetine with pregabalin and with duloxetine plus gabapentin in patients with DPNP.[@b28-jpr-11-1857] Both duloxetine and pregabalin did not worsen diabetes, as measured by changes in glucose and HbA1c in patients with DPNP.

There are limitations in the interpretation of results from this study. Due to the inclusion and exclusion criteria that are inherent to enrolling patients in clinical trials, the patients in this study may not completely represent the general population of patients with DPNP or patients with other forms of diabetic neuropathy, such as radiculoplexus neuropathy or treatment-induced neuropathy. Results from clinical trials are not always indicative of real-world results, as patients vary in their characteristics, levels of adherence, and comorbidities that may affect their response to duloxetine. For example, most of the patients in this study were Japanese, had moderate HbA1c levels, and were relatively young. Potential differences due to gender, ethnicity or cultural considerations may be underrepresented in this sample. In addition, the study period was for a duration of 12 weeks, and consequently this study did not assess long-term effectiveness or safety.

Conclusion
==========

Our study demonstrated the noninferiority of duloxetine compared with pregabalin, as measured by change from baseline in the 24-hour NRS average pain score in patients with DPNP. Overall, duloxetine and pregabalin were well tolerated and the safety profiles were consistent with previously reported results.
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###### 

Patient demographics and baseline characteristics

                                                                                                       Duloxetine (n=152)   Pregabalin (n=151)   Total (N=303)     *P*-value[a](#tfn2-jpr-11-1857){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------- -------------------- -------------------- ----------------- ------------------------------------------------------
  Age (years), mean (SD)                                                                               59.3 (8.16)          60.0 (9.84)          59.6 (9.03)       0.502
  Age (years), n (%)                                                                                                                                               0.130
   \<40                                                                                                2 (1.3)              5 (3.3)              7 (2.3)           
   ≥40 to \<50                                                                                         16 (10.5)            19 (12.6)            35 (11.6)         
   ≥50 to \<60                                                                                         57 (37.5)            37 (24.5)            94 (31.0)         
   ≥60 to \<70                                                                                         61 (40.1)            68 (45.0)            129 (42.6)        
   ≥70 to \<80                                                                                         16 (10.5)            22 (14.6)            38 (12.5)         
  Sex (male), n (%)                                                                                    111 (73.0)           109 (72.2)           220 (72.6)        0.898
  HbA1c (%), mean (SD)                                                                                 7.18 (0.785)         7.35 (0.841)         7.27 (0.816)      0.064
  Duration of diabetes (years), mean (SD)                                                              12.35 (8.087)        12.30 (8.606)        12.33 (8.336)     0.961
  Type of diabetes, n (%)                                                                                                                                          0.378
   Type 1                                                                                              8 (5.3)              4 (2.6)              12 (4.0)          
   Type 2                                                                                              144 (94.7)           147 (97.4)           291 (96.0)        
  Duration of diabetic neuropathy (years)[b](#tfn3-jpr-11-1857){ref-type="table-fn"}, mean (SD)        3.09 (4.281)         2.86 (3.777)         2.97 (4.033)      0.617
  Duration of diabetic neuropathy pain (years)[c](#tfn4-jpr-11-1857){ref-type="table-fn"}, mean (SD)   4.29 (3.871)         4.88 (4.590)         4.59 (4.248)      0.228
  Pain severity (NRS), mean (SD)                                                                                                                                   
   Average pain                                                                                        5.38 (1.079)         5.35 (1.129)         5.37 (1.102)      0.804
   Night pain                                                                                          4.92 (1.650)         4.61 (1.855)         4.76 (1.759)      0.130
   Worst pain                                                                                          6.22 (1.237)         6.25 (1.311)         6.23 (1.273)      0.839
  BPI severity, mean (SD)                                                                                                                                          
   Average pain                                                                                        5.3 (1.17)           5.3 (1.21)           5.3 (1.19)        0.711
   Worst pain                                                                                          6.3 (1.24)           6.3 (1.45)           6.3 (1.35)        0.822
   Least pain                                                                                          3.9 (1.70)           3.8 (1.74)           3.9 (1.72)        0.481
   Pain right now                                                                                      4.9 (1.58)           4.9 (1.60)           4.9 (1.59)        0.996
  NPSI, mean (SD)                                                                                                                                                  
   Total score                                                                                         32.1 (16.49)         31.8 (15.60)         31.9 (16.03)      0.841
   Burning spontaneous pain                                                                            2.5 (2.69)           2.7 (2.83)           --                0.498
   Pressing spontaneous pain                                                                           2.9 (2.19)           2.9 (2.35)           --                0.917
   Paroxysmal pain                                                                                     3.1 (2.31)           3.0 (2.44)           --                0.754
   Evoked pain                                                                                         2.5 (2.15)           2.3 (2.00)           --                0.296
   Paresthesia/dysesthesia                                                                             5.0 (1.97)           5.2 (2.08)           --                0.401
  BPI interference, mean (SD)                                                                                                                                      
   Average of 7 interference scores                                                                    2.63 (1.875)         2.66 (1.744)         2.64 (1.807)      0.885
   General activity                                                                                    3.4 (2.21)           3.1 (2.14)           3.3 (2.18)        0.196
   Mood                                                                                                2.9 (2.23)           3.3 (2.32)           3.1 (2.28)        0.130
   Walking ability                                                                                     2.8 (2.51)           2.9 (2.28)           2.8 (2.39)        0.737
   Normal work                                                                                         2.6 (2.41)           2.6 (2.11)           2.6 (2.26)        0.959
   Relations with other people                                                                         1.4 (1.81)           1.4 (1.81)           1.4 (1.80)        0.799
   Sleep                                                                                               2.8 (2.37)           2.7 (2.39)           2.8 (2.38)        0.579
   Enjoyment of life                                                                                   2.5 (2.24)           2.6 (2.27)           2.5 (2.25)        0.610
  EQ-5D index score, mean (SD)                                                                         0.7337 (0.1230)      0.7253 (0.0903)      0.7296 (0.1079)   0.499
  EQ-5D VAS score, mean (SD)                                                                           60.9 (20.62)         62.1 (18.90)         61.5 (19.76)      0.579
  CGI-S, mean (SD)                                                                                     3.8 (0.72)           3.9 (0.75)           3.9 (0.74)        0.142
  PGI-S, mean (SD)                                                                                     3.9 (0.97)           3.9 (0.85)           3.9 (0.91)        0.895
  BDI-II, mean (SD)                                                                                    6.8 (5.90)           6.2 (5.41)           6.5 (5.66)        0.394

**Notes:** Unless specified, mean (SD) is provided for each variable.

Treatment comparison of *P*-values determined by Fisher's exact test for categorical variables and by analysis of variance for continuous variables;

duration of diabetic neuropathy is that from diagnosis;

duration of diabetic neuropathy pain is that from onset.

**Abbreviations:** BDI-II, Beck Depression Inventory-II; BPI, Brief Pain Inventory; CGI-S, Clinical Global Impression of Severity; DPNP, diabetic peripheral neuropathic pain; EQ-5D, EuroQol5 Dimension; HbA1c, hemoglobin A1c; NPSI, Neuropathic Pain Symptom Inventory; NRS, numeric rating scale; PGI-S, Patient Global Impression of Severity.

###### 

Dose volume

  Week           Dose regimen                                                             
  -------------- -------------- ----------- --------- ----------- ----------- ----------- ----
  Week 4         (n=142)                              (n=144)                             --
  --             83 (58.5)      59 (41.5)   --        90 (62.5)   54 (37.5)               
  Week 8         (n=140)                              (n=136)                             
  --             76 (54.3)      64 (45.7)   --        78 (57.4)   37 (27.2)   21 (15.4)   
  Maximum dose   (n=152)                              (n=151)                             
  5 (3.3)        82 (53.9)      65 (42.8)   3 (2.0)   85 (56.3)   42 (27.8)   21 (13.9)   

###### 

Changes from baseline to week 12 in the secondary measures

  Item                                Duloxetine LS mean (SE)   Pregabalin LS mean (SE)   Treatment difference (95% CI)
  ----------------------------------- ------------------------- ------------------------- -------------------------------
  Pain severity (NRS)                                                                     
   Night pain                         --2.160 (0.131)           --2.166 (0.131)           0.005 (--0.355, 0.366)
   Worst pain                         --2.416 (0.145)           --2.553 (0.145)           0.136 (--0.264, 0.537)
  BPI severity                                                                            
   Average pain                       --2.4 (0.1)               --2.5 (0.1)               0.1 (--0.2, 0.5)
   Worst pain                         --2.7 (0.2)               --2.8 (0.2)               0.1 (--0.3, 0.6)
   Least pain                         --1.9 (0.1)               --1.7 (0.1)               --0.1 (--0.5, 0.2)
   Pain right now                     --2.4 (0.1)               --2.4 (0.1)               0.0 (--0.4, 0.4)
  NPSI                                                                                    
   Total score                        --16.1 (1.1)              --15.4 (1.1)              --0.7 (--3.6, 2.2)
   Burning spontaneous pain           --1.3 (0.2)               --1.1 (0.2)               --0.2 (--0.6, 0.2)
   Pressing spontaneous pain          --1.4 (0.1)               --1.4 (0.1)               0.1 (--0.3, 0.4)
   Paroxysmal pain                    --1.7 (0.1)               --1.7 (0.1)               0.1 (--0.3, 0.4)
   Evoked pain                        --1.2 (0.1)               --1.0 (0.1)               --0.2 (--0.5, 0.2)
   Paresthesia/dysesthesia            --2.6 (0.1)               --2.5 (0.1)               --0.1 (--0.5, 0.3)
  BPI interference                                                                        
   Average of 7 interference scores   --1.77 (0.10)             --1.60 (0.10)             --0.16 (--0.44, 0.11)
   General activity                   --2.1 (0.1)               --1.9 (0.1)               --0.2 (--0.6, 0.1)
   Mood                               --2.1 (0.1)               --1.9 (0.1)               --0.2 (--0.6, 0.2)
   Walking ability                    --1.9 (0.1)               --1.8 (0.1)               --0.1 (--0.4, 0.2)
   Normal work                        --1.8 (0.1)               --1.6 (0.1)               --0.2 (--0.5, 0.1)
   Relations with other people        --0.9 (0.1)               --0.7 (0.1)               --0.2 (--0.4, 0.1)
   Sleep                              --1.7 (0.1)               --1.7 (0.1)               --0.0 (--0.3, 0.3)
   Enjoyment of life                  --1.8 (0.1)               --1.6 (0.1)               --0.2 (--0.5, 0.1)
  EQ-5D index score                   0.1144 (0.0112)           0.1004 (0.0112)           0.0140 (--0.0161, 0.0441)
  EQ-5D VAS score                     9.9 (1.6)                 8.3 (1.6)                 1.6 (--2.6, 5.8)
  CGI-I                               2.5 (0.1)                 2.6 (0.1)                 --0.2 (--0.4, 0.0)
  PGI-I                               2.4 (0.1)                 2.6 (0.1)                 --0.2 (--0.4, 0.1)
  BDI-II                              --2.3 (0.3)               --2.5 (0.3)               0.2 (--0.8, 1.1)

**Notes:** LS mean of actual value is from REML based on the MMRM model or from the analysis of covariance model.

**Abbreviations:** BDI-II, Beck Depression Inventory-II; BPI, Brief Pain Inventory; CGI-I, Clinical Global Impression of Improvement; EQ-5D, EuroQol5 Dimension; LS, least squares; MMRM, mixed-model repeated-measures; NPSI, Neuropathic Pain Symptom Inventory; NRS, numeric rating scale; PGI-I, Patient Global Impression of Improvement; REML, restricted maximum likelihood.

###### 

Frequency of treatment-emergent adverse drug reactions that occurred in at least three patients

  Treatment-emergent adverse drug reactions   Duloxetine (n=152), n (%)   Pregabalin (n=151), n (%)   Fisher's exact *P*-value
  ------------------------------------------- --------------------------- --------------------------- --------------------------
  Patients with ≥1 TEADR                      45 (29.6)                   54 (35.8)                   0.272
  Somnolence                                  18 (11.8)                   22 (14.6)                   0.502
  Dizziness                                   6 (3.9)                     16 (10.6)                   0.028
  Headache                                    3 (2.0)                     0                           0.248
  Nausea                                      11 (7.2)                    5 (3.3)                     0.198
  Vomiting                                    3 (2.0)                     1 (0.7)                     0.623
  Stomatitis                                  3 (2.0)                     0                           0.248
  Feeling abnormal                            1 (0.7)                     4 (2.6)                     0.214
  Edema peripheral                            0                           3 (2.0)                     0.123
  Vertigo                                     2 (1.3)                     3 (2.0)                     0.684
  Decreased appetite                          3 (2.0)                     0                           0.248

**Abbreviation:** TEADR, treatment-emergent adverse drug reaction.

###### 

HbA1c and blood glucose (endpoint change)

  Item (unit)                    Duloxetine   Pregabalin                                          
  ------------------------------ ------------ ------------ ------ --------- ------ ------- ------ -------
  HbA1c (%)                      7.18         7.35         0.17   0.003     7.35   7.50    0.14   0.019
  Fasting glucose (mmol/L)       8.20         9.15         0.81   0.041     8.53   8.70    0.17   0.622
  Non-fasting glucose (mmol/L)   8.65         10.08        1.30   \<0.001   9.24   10.01   0.85   0.039

**Note:** LS mean of change from baseline is from the analysis of covariance model: change from baseline = baseline value + treatment (type III sum of squares). **Abbreviation:** LS, least squares.
